Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of Vemurafenib + Cobimetinib vs Vemurafenib + Placebo in BRAFV600-Mutant Metastatic Melanoma
2012-003008-11Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing Vemurafenib + Cobimetinib with Vemurafenib + Placebo (2 arms). Primary endpoint: Progression-free survival. Started Oct 2012; status: completed.
02
Drugs
vemurafenibcobimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2012-003008-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003008-11.